Bariatric surgery evolution from the malabsorptive to the hormonal era

Obesity Surgery

Volumn 22, Issue 5, 2012, Pages 827-831

  Akkary, Ehab ^a  

^a Preston Memorial Hospital   (United States)

Author keywords

Gastric band; Gastric bypass; Ghrelin; GLP 1; Gut hormones; Peptide YY; Sleeve gastrectomy

Indexed keywords

AMYLIN; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY;

BARIATRIC SURGERY; CLASSIFICATION; COMORBIDITY; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; GASTRIC BANDING; HORMONE ACTION; HORMONE DETERMINATION; HORMONE RELEASE; HUMAN; INTERMETHOD COMPARISON; MALABSORPTION; METABOLIC DISORDER; OUTCOME ASSESSMENT; PANCREAS DUCT; PRIORITY JOURNAL; REVIEW; SLEEVE GASTRECTOMY; SMALL INTESTINE MUCOSA; STOMACH BYPASS; STOMACH FUNDUS; WEIGHT GAIN; WEIGHT REDUCTION;

BARIATRIC SURGERY; FEMALE; HUMANS; MALABSORPTION SYNDROMES; MALE; OBESITY, MORBID; PEPTIDE HORMONES; WEIGHT LOSS;

EID: 84862672106     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-012-0623-2     Document Type: Review

References (44)

1. Kremen A, Linner J, Nelson C. An experimental evaluation of the nutritional importance of proximal and distal small intestine. Ann Surg. 1954;140:439-48.
2. Griffen Jr W, Bivins B, Bell R. The decline and fall of jejunoileal bypass. Surg Gynecol Obstet. 1983;157:301-8.
3. Payne J, DeWind L. Surgical treatment of obesity. Am J Surg. 1969;118:141-7.
4. Rucker R, Chan E, Horstmann J, et al. Searching for the best weight reduction operation. Surgery. 1984;96:624-31. (Pubitemid 14019707)
5. Payne J, Dewind L, Commons R. Metabolic observations in patients with jejunocolic shunts. Am J Surg. 1963;106:273-89.
6. Scopinaro N, Gianetta E, Adami G, et al. Biliopancreatic diversion for obesity at eighteen years. Surgery. 1996;119:261-8. (Pubitemid 26082661)
7. Marceau P, Biron S, Bourque R, et al. Biliopancreatic diversion with a new type of gastrectomy. Obes Surg. 1993;3:29-35. (Pubitemid 23053420)
8. Kuzmak L, Yap I, McGuire L, et al. Surgery for morbid obesity using an inflatable gastric band. AORN J. 1990;51:1307-24.
9. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-60. (Pubitemid 129516334)
10. Yang J, Zhao T, Goldstein J, et al. Inhibition of ghrelin O-acyl-transferase (GOAT) by octanoylated pentapeptides. Proc Natl Acad Sci U S A. 2008;105:10750-5.
11. De Vriese C, Gregoire F, Lema-Kisoka R, et al. Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites. Endocrinology. 2004;145:4997-5005. (Pubitemid 39551118)
12. Cummings D, Purnell J, Frayo R, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50:1714-9. (Pubitemid 33641587)
13. Drazen D, Vahl T, D'Alessio D, et al. Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status. Endocrinology. 2006;147:23-30. (Pubitemid 43004258)
14. Taheri S, Lin L, Austin D, et al. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med. 2004;1:e62.
15. Wren A, Seal L, Cohen M, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992.
16. Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest. 2005;128:1187-93. (Pubitemid 41324394)
17. Cummings D, Weigle D, Frayo R, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623-30. (Pubitemid 34755670)
18. Halem H, Taylor J, Dong J, et al. Novel analogs of ghrelin: physiological and clinical implications. Eur J Endocrinol. 2004;151:S71-5. (Pubitemid 39276351)
19. Kobelt P, Helmling S, Stengel A, et al. Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats. Gut. 2006;55:788-92. (Pubitemid 43764547)
20. Zorrilla E, Iwasaki S, Moss J, et al. Vaccination against weight gain. Proc Natl Acad Sci U S A. 2006;103:13226-31. (Pubitemid 44338944)
21. Cytos Biotechnology. Phase I/IIa clinical trial with obese individuals shows no effect of CYT009-GhrQb on weight loss. Cytos Biotechnology. Press release November 7, 2006. Retrieved 2 June 2009.
22. Tan T, Vanderpump M, Khoo B, et al. Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2004;89:4162-5. (Pubitemid 39071530)
23. Adrian T, Bloom S, Bryant M, et al. Distribution and release of human pancreatic polypeptide. Gut. 1976;17:940-4. (Pubitemid 8027537)
24. Lieverse R, Masclee A, Jansen J, et al. Plasma cholecystokinin and pancreatic polypeptide secretion in response to bombesin, meal ingestion andmodified sham feeding in lean and obese persons. Int J Obes Relat Metab Disord. 1994;18:123-7. (Pubitemid 24056317)
25. Silvestre R, Rodriguez-Gallardo J, Jodka C, et al. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am J Physiol Endocrinol Metab. 2001;280:E443-9.
26. Rushing P, Hagan M, Seeley R, et al. Amylin: a novel action in the brain to reduce body weight. Endocrinology. 2000;141:850-3. (Pubitemid 32250511)
27. Westermark P, Engstrom U, Johnson K, et al. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A. 1990;87:5036-40.
28. Paik K, Jin D, Lee K, et al. Peptide YY, cholecystokinin, insulin and ghrelin response to meal did not change, but mean serum levels of insulin is reduced in children with Prader-Willi syndrome. J Korean Med Sci. 2007;22:436-41.
29. Batterham R, Heffron H, Kapoor S, et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab. 2006;4:223-33. (Pubitemid 44307976)
30. Beckh K, Mönnikes H, Loos S, et al. Low hepatic clearance of peptide YY in the perfused rat liver. Regul Pept. 1992;37:205-12.
31. Adrian T, Ferri G, Bacarese-Hamilton A, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology. 1985;89:1070-7. (Pubitemid 16231572)
32. MDRNA. (2008). MDRNA announces phase 2 trial of PYY(3-36) does not meet weight loss endpoint. MDRNA. Press release 31 July 2008.
33. Pedrazzini T. Importance of NPY Y1 receptor-mediated pathways: assessment using NPY Y1 receptor knockouts. Neuropeptides. 2004;38:267-75. (Pubitemid 39158865)
34. Bataille D, Gespach C, Tatemoto K, et al. Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities. Peptides. 1981;2 Suppl 2:41-4. (Pubitemid 12118280)
35. Baggio L, Huang Q, Brown T, et al. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology. 2004;127:546-58. (Pubitemid 39091903)
36. Orskov C, Wettergren A, Holst J. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol. 1996;31:665-70. (Pubitemid 26290929)
37. Mentlein R, Gallwitz B, Schmidt W. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:829-35. (Pubitemid 23188160)
38. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268-78.
39. Pournaras D, Osborne A, Hawkins S, et al. The gut hormone response following Roux-en-Y gastric bypass: cross-sectional and prospective study. Obes Surg. 2010;20:56-60.
40. Kotidis EV, Koliakos G, Papavramidis T, et al. The effect of biliopancreatic diversion with pylorus-preserving sleeve gastrectomy and duodenal switch on fasting serum ghrelin, leptin and adiponectin levels: is there a hormonal contribution to the weight-reducing effect of this procedure? Obes Surg. 2006;16:554-9. (Pubitemid 43786076)
41. Beckman L, Beckman T, Earthman C. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc. 2010;110:571-84.
42. Bohdjalian A, Langer F, Shakeri-Leidenmühler. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg. 2010;20:535-40.
43. Tzovaras G, Papamargaritis D, Sioka E, et al. Symptoms suggestive of dumping syndrome after provocation in patients after laparoscopic sleeve gastrectomy. Obes Surg. 2011;22(1):23-8.
44. Lee WJ, Chen CY, Chong K, et al. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis. 2011;7(6):683-90.